SCHEMBL2879986

SCHEMBL2879986

CN(C)C1CCCC(N)C1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.33
ADH1C P00326 1/20 0.31
ADH1A P07327 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348145 1.00 TRPM8 (0.33) TRPM8ADH1CADH1A
SCHEMBL22011092 0.97 ADH1C (0.34) TRPM8ADH1CADH1A
SCHEMBL25575437 0.86
SCHEMBL25582860 0.86
SCHEMBL8324578 0.86
SCHEMBL25575435 0.86
SCHEMBL25575438 0.86
Hydrochloric Acid SCHEMBL8327862 0.84
Hydrochloric Acid SCHEMBL8327858 0.84
SCHEMBL21386209 0.80 ADH1A (0.38) ADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2782658-A1 USE OF CYCLIC AMINES FOR REVERSIBLE ABSORPTION OF CO2 Büttner, Hermann (DE) 2014-10-01 EP claimed
WO-2013075697-A1 USE OF CYCLIC AMINES FOR REVERSIBLE ABSORPTION OF CO2 BUETTNER HERMANN (DE) 2013-05-30 WO claimed
EP-0614664-B2 Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-01-08 EP claimed
EP-0614664-B1 Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1998-09-16 EP claimed
US-5519024-A CELL ADHESION INHIBITOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-05-21 US claimed
US-12624265-B2 Antistatic agent, antistatic composition comprising same, antistatic resin composition comprising same, and molded article thereof ADEKA CORPORATION (JP) 2026-05-12 US disclosed
US-20250163281-A1 THERMOPLASTIC RESIN COMPOSITION FOR FUSED DEPOSITION MODELING, MODELED BODY, AND METHOD FOR PRODUCING SAME ADEKA CORPORATION (JP) 2025-05-22 US disclosed
US-20250161906-A1 METHOD FOR REMOVING GASES EVONIK OPERATIONS GMBH (DE) 2025-05-22 US disclosed
EP-4556101-A1 GAS REMOVAL METHOD Evonik Operations GmbH (DE) 2025-05-21 EP disclosed
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 US disclosed
EP-4484465-A1 THERMOPLASTIC RESIN COMPOSITION FOR FUSED DEPOSITION MODELING, MODELED BODY, AND METHOD FOR PRODUCING SAME ADEKA CORPORATION (JP) 2025-01-01 EP disclosed
US-20240059677-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR CEREVANCE LTD (GB) 2024-02-22 US disclosed
EP-0614664-B1 Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1998-09-16 EP disclosed
US-5703081-A CELL ADHESION INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-12-30 US disclosed
EP-0802214-A1 Water soluble resins and application thereof to paper coating SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1997-10-22 EP disclosed
US-5521240-A PIGMENTS, BINDERS AND REACTION OF ALKYLENEDIAMINE, UREA, ALDEHYDE, EPIHALOHYDRIN AND AMIDE OR AMINONITRILE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-05-28 US disclosed
US-5519024-A CELL ADHESION INHIBITOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-05-21 US disclosed
EP-0691432-A2 Paper coating composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-01-10 EP disclosed
CN-1099029-A Carbostyril carboxylic acid derivatives, its preparation and purposes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-02-22 CN disclosed
EP-0614664-A1 Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 TRPM8 3604/4885ADH1C 185/4885ADH1A 387/4885
US-20240059677-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR CHRNA6, CHRM2, CHRNA1 TRPM8 940/4885ADH1C 539/4885ADH1A 335/4885
US-12624265-B2 Antistatic agent, antistatic composition comprising same, antistatic resin composition comprising same, and molded article thereof SORD, SUCLA2, SUCLG1 TRPM8 3532/4885ADH1C 676/4885ADH1A 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.